From the Guidelines
Rimona, also known as Rimantadine, is an antiviral medication primarily used for the prophylaxis and treatment of influenza A virus infections. The medication is approved for use in adults and children over 1 year of age, with specific dosage recommendations based on age and weight 1.
- For children aged 1-9 years, the recommended dosage is 5 mg/kg body weight/day, not to exceed 150 mg/day.
- For children aged 10 years and older, the recommended dosage is 200 mg/day, but for those weighing less than 40 kg, the dosage should be 5 mg/kg body weight/day. It's essential to note that Rimantadine is not effective against influenza B viruses and has high levels of resistance among currently circulating influenza A viruses, making it less favorable compared to other antiviral medications like oseltamivir, zanamivir, and peramivir 1. The use of Rimantadine should be considered in specific patient populations, taking into account factors such as age, weight, renal function, and potential interactions with other medications 1. However, based on the most recent evidence, Rimantadine is not recommended for use due to high levels of resistance among circulating influenza A viruses 1.
From the Research
Rimona Usage
- There is no direct information available on Rimona in the provided studies 2, 3, 4, 5, 6.
- The studies focus on various topics such as medication during severe infections 2, providing physicians with feedback on medication adherence 3, use of antibiotics in chronic obstructive pulmonary disease 4, common severe infections in chronic granulomatous disease 5, and antibiotic therapy in exacerbations of chronic obstructive pulmonary disease 6.
- None of the studies mention Rimona, and therefore, its usage cannot be determined based on the provided evidence.